Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Language
Publication year range
1.
J Allergy Clin Immunol Pract ; 11(2): 431-438.e2, 2023 02.
Article in English | MEDLINE | ID: mdl-36272718

ABSTRACT

BACKGROUND: Real-world evidence (RWE) is a valuable instrument to better understand the patient journey and effectiveness of therapies. RWE on the prevalence of uncontrolled chronic rhinosinusitis (CRS) and CRS natural course of disease across Europe is scarce. In addition, there is limited RWE that enables comparison of the effectiveness of marketed therapies including topical or systemic corticosteroids, sinus surgery, or biologics. OBJECTIVE: To establish an international CHRonic rhINOSinusitis Outcome Registry (CHRINOSOR) based on real-world data collection enabled by mobile health technology. METHODOLOGY: A digital platform, Galenus Health, supporting patients and physicians in the management of chronic respiratory diseases, is used to collect data on patient profile, disease history, patient outcomes, and a set of relevant clinical outcomes. Adult patients with a diagnosis of CRS are eligible for inclusion. RESULTS: A collaborative scientific network of 17 university ear-nose-throat (ENT) clinics from 10 European countries has been established with the aim to collect real-world data in a longitudinal and standardized manner. The Galenus Health digital platform is currently being implemented in these ENT clinics taking into account legal, privacy, and data security aspects. Up to 300 patients have already been included. CONCLUSIONS: CHRINOSOR is a collaborative effort that aims at improving our understanding of CRS, its comorbidities, and the effectiveness of its treatments. Ultimately, these insights will guide us as scientific community to develop future care pathways informed by RWE.


Subject(s)
Nasal Polyps , Rhinitis , Sinusitis , Adult , Humans , Nasal Polyps/drug therapy , Rhinitis/therapy , Rhinitis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Sinusitis/therapy , Sinusitis/drug therapy , Chronic Disease
2.
Allergy ; 75(11): 2867-2878, 2020 11.
Article in English | MEDLINE | ID: mdl-32424899

ABSTRACT

BACKGROUND: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient-reported outcomes by mobile technology offers the possibility to better understand real-life burden of CRS. METHODS: This study reports on the cross-sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria. RESULTS: The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major symptoms. Approximately half of patients reported nasal polyps. 47.3% of all CRS patients were uncontrolled based on evaluation of VAS global rhinosinusitis symptom score compared to 40.9% based on adapted EPOS criteria. The impact of CRS on sleep quality and daily life activities was significantly higher in uncontrolled versus well-controlled patients. Half of patients had a history of FESS (functional endoscopic sinus surgery) and reported lower symptom severity compared to patients without a history of FESS, except for patients with a history of more than 3 procedures. Patients with a history of FESS reported higher VAS levels for impaired smell. CONCLUSION: Real-life data confirm the high disease burden in uncontrolled CRS patients, clearly impacting quality of life. Sinus surgery improves patient-reported outcomes, but not in patients with a history of more than 3 procedures. Mobile technology opens a new era of real-life monitoring, supporting the evolution of care towards precision medicine.


Subject(s)
Nasal Polyps , Rhinitis , Sinusitis , Chronic Disease , Cross-Sectional Studies , Humans , Nasal Polyps/epidemiology , Quality of Life , Rhinitis/diagnosis , Rhinitis/epidemiology , Sinusitis/diagnosis , Sinusitis/epidemiology
3.
Bousque, Jean; Schunemann, Holger J; Togias, Akdis; Bachert, Claus; Erhola, Martina; Hellings, Peter W; Klimek, Ludger; Pfaar, Oliver; Wallace, Dana; Ansotegui, Ignacio; Agache, Ioana; Bedbrook, Anna; Bergmann, MKarl-Christian; Bewick, Mike; Bonniaud, Philippe; Bosnic-Anticevich, Sinthia; Bosse, Isabelle; Bouchard, Jacques; Boulet, Louis-Philippe; Brozek, Jan; Brusselle, Guy; Calderon, Moises A; Canonica, Walter G; Caraballo, Luis; Cardona, Vicky; Casale, Thomas; Cecchi, Lorenzo; Chu, Derek K; Costa, Elisio M; Cruz, Alvaro A; Czarlewski, Wienczyslawa; D'Amato, Gennaro; Devillier, Philippe; Dykewicz, Mark; Ebisawa, Motohiro; Fauquert, Jean-Louis; Fokkens, Wytske J; Fonseca, Joao A; Fontaine, Jean-Francois; Gemicioglu, Bilun; van Wijk, Roy Gerth; Haahtela, Tari; Halken, Susanne; Ierodiakonou, Despo; Iinuma, Tomohisa; Ivancevich, Juan-Carlos; Jutel, Marek; Kaidashev, Igor; Khaitov, Musa; Kalayci, Omer; Tebbe, Jorg Kleine; Kowalski, Marek L; Kuna, Piotr; Kvedariene, Violeta; La Grutta, Stefania; Larenas-Linnemann, Desiree; Lau, Susanne; Laune, Daniel; Le, Lan; Lieberman, Philipp; Lodrup Carlsen, Karin C; Lourenço, Olga; Marien, Gert; Carreiro-Martins, Pedro; Melen, Erik; Menditto, Enrica; Neffen, Hugo; Mercier, Gregoire; Mosgues, Ralph; Mullol, Joaquim; Muraro, Antonella; Namazova, Leyla; Novellino, Ettore; O'Hehir, Robyn; Okamoto, Yoshitaka; Ohta, Ken; Park, Hae Sim; Panzner, Petr; Passalacqua, Giovanni; Pham-Thi, Nhan; Price, David; Roberts, Graham; Roche, Nicolas; Rolland, Christine; Rosario, Nelson; Ryan, Dermot; Samolinski, Boleslaw; Sanchez-Borges, Mario; Scadding, Glenis K; Shamji, Mohamed H; Sheikh, Aziz; Bom, Ana-Maria Todo; Toppila-Salmi, Sanna; Tsiligianni, Ioana; Valentin-Rostan, Marylin; Valiulis, Arunas; Valovirta, Erkka; Ventura, Maria-Teresa; Walker, Samantha; Waserman, Susan; Yorgancioglu, Arzu; Zuberbier, Torsten.
J. allergy clin. immunol ; 145(1): [70-80], Jan. 2020.
Article in English | BIGG - GRADE guidelines | ID: biblio-1117204

ABSTRACT

The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.


Subject(s)
Humans , Rhinitis, Allergic, Seasonal/prevention & control , Treatment Outcome , Anti-Allergic Agents/therapeutic use , Rhinitis, Allergic/prevention & control , Rhinitis, Allergic/drug therapy
6.
Allergy ; 74(12): 2312-2319, 2019 12.
Article in English | MEDLINE | ID: mdl-31090937

ABSTRACT

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.


Subject(s)
Asthma/complications , Biological Products/therapeutic use , Nasal Polyps/complications , Rhinitis/complications , Rhinitis/drug therapy , Sinusitis/complications , Sinusitis/drug therapy , Biological Products/administration & dosage , Biological Products/adverse effects , Chronic Disease , Clinical Decision-Making , Comorbidity , Disease Management , Health Services Needs and Demand , Humans , Research , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...